{
    "clinical_study": {
        "@rank": "25191", 
        "arm_group": [
            {
                "arm_group_label": "Sofosbuvir+RBV 16 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 24 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, randomized, open-label study to evaluate the antiviral efficacy,\n      safety, and tolerability of sofosbuvir+ribavirin (RBV) in treatment-naive adults with\n      chronic genotype 1 or genotype 3 hepatitis C virus (HCV) infection."
        }, 
        "brief_title": "Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV RNA \u226510^4 IU/mL at screening\n\n          -  Confirmed chronic HCV genotype 1 or 3 infection\n\n          -  HCV treatment naive\n\n          -  Approximately 30% of subjects may have compensated cirrhosis at screening\n\n        Exclusion Criteria:\n\n          -  Any other chronic liver disease\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\n          -  Current or prior history of clinical hepatic de-compensation\n\n          -  Contraindication to RBV therapy, e.g., history of clinically significant\n             hemoglobinopathy (sickle cell disease, thalassemia).\n\n          -  Chronic use of systemically administered immunosuppressive agents\n\n          -  History of solid organ transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074514", 
            "org_study_id": "GS-US-334-0116"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 16 weeks", 
                    "Sofosbuvir+RBV 24 weeks"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sovaldi\u00ae", 
                    "GS-7977", 
                    "PSI-7977"
                ]
            }, 
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 16 weeks", 
                    "Sofosbuvir+RBV 24 weeks"
                ], 
                "description": "RBV 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "state": "Andhra Pradesh", 
                        "zip": "500 004"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "state": "Andhra Pradesh", 
                        "zip": "500082"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "state": "Delhi", 
                        "zip": "110029"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "state": "Delhi", 
                        "zip": "110070"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surat", 
                        "country": "India", 
                        "state": "Gujarat", 
                        "zip": "395002"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gurgaon", 
                        "country": "India", 
                        "state": "Haryana", 
                        "zip": "122 001"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kochi", 
                        "country": "India", 
                        "state": "Kerala", 
                        "zip": "682040"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "400012"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ludhiana", 
                        "country": "India", 
                        "state": "Punjab", 
                        "zip": "141001"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jaipur", 
                        "country": "India", 
                        "state": "Rajasthan", 
                        "zip": "302004"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbatore", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "641 005"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "state": "Uttarpradesh", 
                        "zip": "226014"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Kolkata", 
                        "country": "India", 
                        "state": "West Bengal", 
                        "zip": "700 020"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Chandigarh", 
                        "country": "India", 
                        "zip": "160012"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Na\u00efve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection", 
        "overall_contact": {
            "email": "gs3340116study@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Kathryn Kersey, MSc", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.", 
                "measure": "Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "Virologic failure is defined as either:\nVirologic breakthrough (participant achieved undetectable HCV RNA levels during treatment but subsequently had detectable HCV RNA while continuing treatment), or\nNon-response (HCV RNA \u2265 LLOQ through 16 or 24 weeks of treatment)\nViral relapse is defined as:\nParticipant achieved undetectable HCV RNA levels during treatment maintained undetectable HCV RNA for the duration of treatment or achieved undetectable HCV RNA within 4 weeks of the end of treatment but did not achieve SVR at 4, 12, or 24 weeks posttreatment.", 
                "measure": "Proportion of participants with virologic failure and viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Baseline to posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}